CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion
CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase...
Read MoreCatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference
CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002...
Read MoreCatalYm Presents Updated Tolerability & Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human Clinical Trial...
CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human...
Read MoreCatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference...
CatalYm To Present Update from GDF-15 Targeting First-in-Human I/O Clinical Trial in...
Read MoreCatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting
CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody...
Read MoreCatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation
CatalYm Presents at Bioequity Europe May 17-19 2021 – view presentation CatalYm-Bioequity-Corp-presentation-May-2021...
Read MoreCatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer Munich,...
Read MoreCatalYm Announces Key Management and Board Changes
CatalYm Announces Key Management and Board Changes Dr. Manfred Ruediger steps down...
Read MoreCatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer
CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002...
Read MoreCatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients
CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for...
Read More